1. 14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). Issue 3 (September 2015) Authors: Vansteenkiste, J.; Fehrenbacher, L.; Spira, A.I.; Mazieres, J.; Park, K.; Smith, D.; Artal-Cortes, A.; Lewanski, C.; Braiteh, F.; Yi, J.; He, P.; Kowanetz, M.; Waterkamp, D.; Ballinger, M.; Chen, D.S.; Sandler, A.; Rittmeyer, A. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S716 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). (September 2015) Authors: Besse, B.; Johnson, M.; Janne, P.A.; Garassino, M.; Eberhardt, W.E.E.; Besse, B.; Johnson, M.; Janne, P.A.; Garassino, M.; Eberhardt, W.E.E.; Peters, S.; Toh, C.K.; Kurata, T.; Li, Z.; Kowanetz, M.; Mocci, S.; Sandler, A.; Rizvi, N.A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S717 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2877 Characterization of PD-L1 expression and immune cell infiltration in Nasopharyngeal Cancer (NPC). (September 2015) Authors: Chan, O. S.H.; Kowanetz, M.; Ng, W.T.; Koeppen, H.; Chan, L.K.; Yeung, R. M.W.; Amler, L.; Hegde, P.; Mancao, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S582 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes. (September 2015) Authors: Schmid, P.; Kowanetz, M.; Koeppen, H.; Zou, W.; Wistuba, I.; Kockx, M.; Kadel, E.E.; Chaft, J.; Rizvi, N.A.; Hirsch, F.R.; Smith, D.; Miley, N.; Leveque, V.; Shames, D.S.; Sandler, A.; Mellman, I.; Chen, D.S.; Hegde, P.S.; Gettinger, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S602 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 440 Characterization of tumor immune biomarker landscape and its clinical associations in non-small-cell lung carcinoma (NSCLC). (September 2015) Authors: Theelen, W.S.; Schulze, K.; Zou, W.; Peters, D.D.; Do, A.; Sarma, P.; Blaauwgeers, J.L.; Van Noesel, C.; Teiko, S.; Amler, L.C.; Willems, S.M.; Hegde, P.S.; Van den Heuvel, M.M.; Kowanetz, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in non-small cell lung carcinoma patients responding to atezolizumab treatment. (March 2019) Authors: Fehlings, M.; Nardin, A.; Jhunjhunwala, S.; Kowanetz, M.; O'Gorman, B.; Hegde, P.; Li, J.; Sumatoh, H.; Lee, B.; Kim, L.; Flynn, S.; Ballinger, M.; Newell, E.; Yadav, M. Journal: European journal of cancer Issue: Volume 110(2019)Supplement 1 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. (January 2019) Authors: von Pawel, J.; Bordoni, R.; Satouchi, M.; Fehrenbacher, L.; Cobo, M.; Han, J.Y.; Hida, T.; Moro-Sibilot, D.; Conkling, P.; Gandara, D.R.; Rittmeyer, A.; Gandhi, M.; Yu, W.; Matheny, C.; Patel, H.; Sandler, A.; Ballinger, M.; Kowanetz, M.; Park, K. Journal: European journal of cancer Issue: Volume 107(2019) Page Start: 124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗